On 22 April 2022, Biogen announced that it had notified the European Medicines Agency about the withdrawal of its marketing authorisation application for aducanumab, for the treatment of early Alzheimer’s disease.
On 26 April 2022, Alzheimer Europe held an online session of its popular Alzheimer's Association Academy series, bringing together representatives of its member organisations, the European Working Group of People with Dementia, pharmaceutical companies and researchers. The topic for this session was "giving a voice to people with dementia".
On 28 April 2022, Alzheimer Europe and the European Association of Service Providers for Persons with Disabilities (EASPD) signed a Memorandum of Understanding, to provide the basis for future collaboration.
The call for abstracts for the 32nd Alzheimer Europe Conference (#32AEC), "Building Bridges”, which will take place in Bucharest, Romania, from 17 to 19 October 2022, will soon close. The deadline for submissions is 15 May 2022.